Allogene Therapeutics, Inc. (ALLO) Tops Q4 EPS by 4c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q4 EPS of ($0.28), $0.04 better than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• EU approves Arrowhead's plozasiran for rare triglyceride disorder
• Texas AG Paxton announces ongoing investigation into Carnival over data breach